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8detail elsewhere.2-4 Only a brief description of some major
points in these areas as relevant to the primary scope are
provided where necessary in this presentation.
MATERIAL AND METHODS
Three hundred and four limbs (12 bilateral) in 292
patients underwent consecutive stent deployment for the
correction of iliac venous stenosis at River Oaks Hospital
during the period from December 1997 to November
2000. A prior group of 29 consecutive limbs underwent
operation with a different stent technique and have been
described elsewhere.2 After those procedures, substantial
modifications were made. Thus, those cases have been
excluded from this study.
Concurrent procedures. Fifty-six limbs underwent
stripping of the long saphenous vein (LSV) in the thigh
(27 with stab avulsion of associated nontruncal varices),
and five others underwent heat closure of the LSV with
the radiofrequency probe. Together, these 61 limbs were
grouped as a subset and designated as the stent + LSV
group for outcome comparisons.
Clinical presentation. All the patients were seen with
one or more of the following conditions: leg swelling
(eight cases with recurrent cellulitis), leg pain, stasis skin
changes, or ulcer. A detailed breakdown of clinical presen-
tation and severity represented with CEAP classification is
shown in Table I, A. The patients in the C2 category
(varices) in this series had significant associated calf or 
The incidence rate of chronic venous insufficiency
(CVI) in the general population is estimated to be 10% to
15%.1 In recent years, significant advances in diagnostics,
surgical technique, instrumentation, and devices have
occurred. Despite these advances, the therapeutic benefit
for most patients with CVI, particularly those with deep
venous disease, has been limited because the more special-
ized techniques, such as valve reconstruction or bypass
grafting procedures, are still largely confined to a few
select centers. The rapid emergence of endovascular stent
technology offers the prospect of quick widespread adop-
tion for use in venous cases because the basic technique is
already in broad use. Initial experience with this method
indicates excellent patency and surprisingly high symptom
resolution. Herein, we review our clinical experience with
iliac vein stent placement. The scope of the manuscript
will be restricted to the clinical outcome of the device. The
aspects of patient selection, assessment, technique, hemo-
dynamic features, and pathology have been described in
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The clinical impact of iliac venous stents in the
management of chronic venous insufficiency
Seshadri Raju, MD, Sam Owen, Jr, BS, and Peter Neglen, MD, Jackson, Miss
Purpose: The purpose of this study was the presentation of the results of iliac venous stent placement in the manage-
ment of chronic venous insufficiency (CVI).
Methods: Balloon dilation and stent placement for the relief of iliac vein stenoses was performed in 304 limbs with symp-
tomatic CVI. Sixty-one limbs had concomitant saphenous vein ablation. The median age was 52 years (range, 14 to 83
years). The ratio of postthrombotic to nonthrombotic CVI was 1 to 0.9. The CEAP classification clinical scores were:
C2, 24; C3, 158; C4, 60; C5, 13; and C6, 49. Associated reflux was present in 57% of the limbs. The procedure was per-
formed on an outpatient basis. Intravascular ultrasound scanning was routinely performed because transfemoral venog-
raphy had poor sensitivity for the detection of iliac vein stenosis.
Results: The actuarial primary and secondary stent patency rates at 24 months were 71% and 90%, respectively. The
median degree of swelling (graded 0 to 3, for none, pitting, ankle edema, to gross leg edema) declined from grade 2
to grade 1 after surgery (P < .001). The limbs without any swelling increased from 12% before stenting to 47% after
stenting (P < .01). The pain level recorded on a visual analogue scale from 0 to 10 declined from a median level of 4
to 0 after stent placement (P < .001). The limbs that were completely free of pain increased from 17% before stenting
to 71% after stent placement (P < .001). Stasis dermatitis/ulceration was present in 69 limbs. The improvement in
swelling and pain was similar in ulcerated and nonulcerated limbs. The cumulative recurrence-free ulcer healing rate
was 62% at 24 months. The rate of ulcer healing was similar whether or not concomitant saphenous ablation was per-
formed. Quality of life has significantly improved.
Conclusion: The correction of iliac vein outflow obstruction with the placement of stents results in the significant relief
of major symptoms of CVI. The procedure is minimally invasive, can be performed on an outpatient basis, has minimal
complications with a high patency rate, and does not preclude subsequent open surgery for the correction of restenosis
or the associated reflux. If these preliminary results are sustained for a long-term period, stent placement for the cor-
rection of iliac vein stenoses may represent a useful advance in the management of CVI. (J Vasc Surg 2002;35:8-15.)
diffuse leg pain as well. Objective swelling was graded with
physical examination in the following manner: grade 0,
none; grade 1, pitting, not obvious; grade 2, ankle edema;
and grade 3, obvious swelling involving the limb. A sub-
jective scoring of swelling severity obtained with patient
history on the basis of the time of appearance of the
swelling during the work day as recommended in the
Reporting Standards5 was also implemented after its pub-
lication last year (grades 0 to 3: no edema, evening edema,
afternoon edema, morning edema). The level of pain was
measured with the visual analogue scale method.6 The
patient indicated the level of pain on a visual analogue
scale (0 to 10) with the markings and numbers hidden to
the patient but visible to the examiner. This method has
been shown to be highly reliable in tracking pain level
response to therapeutic intervention in the individual
patient. The patients were asked to complete a quality-of-
life questionnaire validated for the assessment of CVI7
prospectively before stent placement and again at each fol-
low-up clinic visit. The last available completed question-
naire for each patient was used in the assessment of this
outcome measure. Numerical grades (1 to 5) were pro-
vided for each question that allowed the patient to assign
a numeric value to the answers.
Preoperative work-up. The preoperative work-up
included complete duplex scan venous examination,
venous functional studies (ambulatory venous pressure, air
plethysmography), and transfemoral venography. A com-
plete hypercoagulability profile was obtained as a guide to
the need for postoperative warfarin therapy, its strength
and duration, but patients were not excluded if the test
results were positive.
Placement of venous stent. Stent placement was rec-
ommended for significant clinical symptoms in patients
whose conditions were refractory or intolerant to conser-
vative therapy. Fully informed consent was obtained. The
details of patient selection and stent placement technique
have been described in full elsewhere.2,3 Briefly, access to
the iliac venous segment was obtained through ipsilateral
femoral venous puncture at the mid-thigh level with ultra-
sound scan guidance. A low venipuncture site assured sat-
isfactory access to the entire iliac venous segment and the
adjacent common femoral vein without restriction by the
sheath. Because the sensitivity of transfemoral venography
for the identification of significant iliac vein stenoses was
poor, intravascular ultrasound scanning (IVUS) was used
for the identification or confirmation of treatable lesions
before stent placement, often at the same session. After
balloon dilatation, placement of venous stent was manda-
tory because recoil of the dilated stenosis otherwise
occurred.2,3,8,9 A 14-mm or 16-mm stent that corre-
sponded to the size of the healthy undiseased iliac vein was
uniformly used. The extension of the iliac stent into the
inferior vena cava was shown from prior experience to be
important to avoid development of iliac vein ostial steno-
sis.2,3 In no instance did thrombosis of the inferior vena
cava or the contralateral iliac vein occurr from this prac-
tice, even when the ipsilateral stent became thrombosed or
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occluded. The use of an adequate length of stent to cover
all stenotic lesions and to avoid interval “skip areas” of
native vein between closely adjacent (<5 cm) stents was
necessary to avoid recurrent stenosis. The procedure was
performed percutaneously on a 23-hour admit basis. The
patients in this series underwent once-a-day aspirin ther-
apy (81 mg) after the procedure. Warfarin therapy was
instituted if a clearly hypercoagulable state was present,
particularly with evidence of prior venous thrombosis.
Patients with marginal titer abnormalities without prior
venous thrombosis did not undergo warfarin therapy. In
any case, warfarin therapy was continued if the patient was
already on warfarin therapy for these or other indications.
In such instances, warfarin therapy was supplemented with
a twice-a-week dose of 81 mg each of aspirin.
Follow-up examination. The patients were seen at 6
weeks after the placement of the stent for clinical evaluation,
transfemoral venography for the assessment of stent
patency, and repeat venous functional studies. Thereafter,
the patients were seen at 4-month to 6-month intervals for
follow-up clinical examination. Clinical deterioration
prompted repeat venography and venous functional studies.
Data collection and statistics. All the clinical data,
including the severity scores, were contemporaneously
entered at each patient visit into a time-stamped electronic
medical record database and analyzed later for this manu-
script. Nonparametric Wilcoxon signed rank test was used
for the comparison of preoperative and postoperative val-
ues. Actuarial data have been used where appropriate for
the presentation of results. Some variations in individual
values for the various parameters will be noted because rel-
evant data were missing in some limbs or because the para-
meter measurement was implemented mid course during
the study period.
RESULTS
There were no technical failures in stenotic lesions
because all such lesions were successfully crossed and
treated. Seventeen totally occluded iliac venous segments
were successfully recanalized (included in this series), but
four others were technical failures during the same time
period (excluded from this series). There were no proce-
dure-related complications, and the 6-week mortality rate
was nil. Reintervention was required in 44 limbs because
of restenosis (>50% stenosis with transfemoral venogra-
phy/IVUS) in 39 limbs and occlusion in five limbs. Two
limbs in the latter group (included in analysis as failed
stents) subsequently underwent a Palma procedure for sal-
vage after reintervention failed to restore patency.
The mean follow-up period was 9 months, and the
range was 1 to 41 months. Follow-up data were available
in 87% of the limbs.
The median age of the patients was 52 years (range,
14 to 83 years), the male to female ratio was 1:2, and the
left to right ratio was 2:1. Hypercoagulability was present
in 48 patients (16%) with the following conditions: pro-
tein C (14 cases, eight severe), protein S (16 cases, six
severe), antithrombin III (14 cases, three severe), lupus
anticoagulant (three cases), anticardiolipin antibody Igg
(seven cases, three severe), anticardiolipin antibody Igm
(six cases, three severe), factor V mutation (11 cases),
homocysteinemia (eight cases, one with homocysteine
gene), and prothrombin gene mutation (one case). In 32
patients, more than a single factor was involved. The
common combinations were: anticardiolipin antibody
and others, factor V mutation and others, and combina-
tions of protein C, protein S, and antithrombin III defi-
ciencies. The venous lesion was considered nonthrombotic
(web, stricture, or May-Thurner syndrome) in 142 cases.
A postthrombotic cause was apparent with venographic
or IVUS examination results in 162 limbs (ratio, 0.9:1).
Only one stent was needed in 61% of the limbs, two stents
were needed in 27% of the limbs, and three or more stents
each were needed in 11% of the limbs. One hundred and
thirty-two patients had isolated obstruction, and 172
(57%) had associated reflux (deep system alone in 9% [n
= 15], deep and perforators in 1% [n = 2], superficial
system alone in 38% [n = 65], and a combination in 52%
[n = 90]; Table I, B). Deep reflux thus was present in
35% of the entire group of 304 limbs. Forty-nine
patients had open ulcers (C6), and in 13 cases, the
recurrent ulcer was closed (C5) at the time of stent
placement (Table II). There were seven additional limbs
with stasis dermatitis/eczema included with C4 classifi-
cation in Table IA as well. Associated reflux was present
in 91% (63 of 69) of these limbs with various forms of
venous stasis skin changes.
The actuarial patency rate of the stents is shown in 
Fig 1. Proof of patency/occlusion was on the basis of ini-
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tial post-stent transfemoral venographic results (n = 223)
and subsequent duplex scan/venographic follow-up
examination results.
Primary and primary assisted/secondary patency rates
(corrective intervention for stenosis/thrombosis) were
71% and 97%, respectively, at 24 months. There was no
correlation between hypercoagulable state and stent
occlusion/stenosis.
The incidence rate of ulcer healing after stent place-
ment is also shown in Table II and in actuarial form (62%
at 2 years) in Fig 2. None of the closed ulcers recurred
during the follow-up period. Seven limbs with venous der-
matitis/eczema included with C4 classification had their
skin lesions resolved.
Swelling and pain severity scores improved significantly
after stent placement (Tables III and IV).Both the subjec-
tive and objective severity scores for swelling improved. Of
note, limbs that were free of any objective swelling
increased from 12% to 47% (P < .001) and limbs that were
totally free of pain increased from 17% to 71% (P < .001)
after stent placement. Recurrent cellulitis resolved in all
eight limbs with this type of primary presentation.
Because a stasis ulcer by itself can be the source of
pain and local swelling apart from that caused by the iliac
vein stenosis, these outcome measures were separately
analyzed for ulcerated and non-ulcerated limbs (Table V).
These outcome measures improved significantly (P <
.001) after stent placement in both subsets. It is note-
worthy that pain severity was the same and swelling was
actually worse in the non-ulcerated limbs as compared
with the ulcerated limbs. This highlights the important
Fig 1. Actuarial patency rate (primary and primary assisted/secondary) of iliac venous stents. Limbs at risk
at each interval for two categories are shown in lower panel.
contribution of non-ulcer pain and swelling in sympto-
matic iliac vein obstruction.
Concurrent long saphenous vein stripping (stent +
long saphenous vein). Improvement in swelling, pain, or
ulcer healing was similar and significant in this group after
stent placement, whether or not an ulcer was present, and
there was no difference in these outcome measures when
stent placement was performed alone without LSV abla-
tion (Table VI). Notably 58% of ulcers healed after stent
placement alone as compared with 54% in the stent + LSV
group (P value was not significant).
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Quality of life. After stent placement, patients (n =
136) experienced improved quality of life in all major cat-
egories addressed in the questionnaire. The categories
were subjective pain, sleep disturbance, morale, and social
activities, routine and strenuous physical activities (P <
.025 or better for each category).
DISCUSSION
Approximately 17% of all the limbs evaluated for CVI
in our clinic currently undergo stent placement.4 It appears
that the real incidence rate of obstructive lesions in CVI
Fig 2. Actuarial ulcer-free interval after stent placement. Only ulcers that were active (C6) at time of stent
insertion are included. Grace period of 4 months for ulcer healing was allowed in constructing curve.
Ulcers that did not heal within time period were scored as unhealed for first time at 4 months. Limbs at
risk at each interval are shown at lower panel. See Table II for data on all limbs with severe skin changes
(C4, C5, and C6).
Table I, A. Clinical severity (CEAP classification) of symptoms in 304 limbs with CVI
Clinical severity
C2 C3 C4* C5 C6
Asymptomatic 3 29 1 1 4
Symptomatic 21 129 59 12 45
Total number 24 158 60 13 49
*Includes 53 limbs with hyperpigmentation and seven limbs with stasis dermatitis/eczema.
Table I, B. Anatomy involvement and type of pathology
Deep system Super/deep system Deep/perforator
Reflux/obstruction 15 155 2
Obstruction only 132 0 0
Total number 147 155 2
may be much higher than generally suspected because the
traditional diagnostic techniques, such as ascending phle-
bography, are poorly sensitive in the identification of these
lesions. The current trend towards increasing reliance on
duplex scanning to the exclusion of phlebography in the
investigation of CVI is likely to further worsen the already
low detection rate of these lesions. A high index of suspi-
cion along with the complete investigation of patients with
CVI, including use of relevant invasive diagnostic tech-
niques when appropriate (patients with significant pain,
swelling, or stasis skin changes), is responsible for the
noted high detection rate of obstructive pathology in our
own practice. Patients with CVI, particularly those with
postthrombotic variety, are seen with symptom severity
that is often disproportionately high as compared with the
meager clinical signs present. It is easy to underestimate the
morbidity in terms of pain and limb discomfort experi-
enced by these patients unless a targeted history with a
severity scale is used for assessment(Table V). For the same
reasons, workplace disability from this affliction is much
higher than generally recognized.10
The relief of iliac venous obstruction with balloon
dilation and stent placement clearly relieves in the short
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term the major symptoms of CVI, with significant resolu-
tion of pain, swelling, stasis dermatitis, and even ulcera-
tion. Quality of life is improved. Stent placement is a
minimally invasive procedure performed on a short hospi-
tal stay basis, and the recuperative time is negligible. Stent
patency rate is high, and the morbidity rate is low. For
these reasons, it is a superior choice over open surgery,
such as a veno-venous bypass grafting, when either choice
is available in the clinical setting. Furthermore, subsequent
open bypass grafting surgery is not precluded if the stent
were to fail with thrombosis or development of restenosis.
Valve reconstruction can be performed, as well, for the
correction of associated reflux. Because of its relative sim-
plicity as compared with invasive surgery, venous stent
placement has the potential to reach and benefit a larger
group of patients with CVI, particularly those with post-
thrombotic disease, than is currently the case with the
more complex bypass grafting or valve reconstruction
techniques. Some caveats, however, are in order. Because
the technology is new, the cost of endovascular supplies,
particularly that of the stent, is relatively high; moderation
of costs as the result of an increase in the number of sup-
ply sources and other factors is expected in the near future.
Table II. Limbs (n = 62) with active ulcer or healed previous ulcer (C5 + C6)
Active ulcer (n = 49) Healed ulcer (n = 13)
Median follow-up period (months) 7 (range, 2 to 35) 9 (range, 2 to 23)
Number of limbs for follow-up examination 41 (84%) 12 (92%)
Healed 28 (68%)* –
Improved 8 (16%)* –
Recurred 2 (4%)* 0
Unchanged 5 (12%)* –
Seven other limbs with stasis dermatitis/eczema (included in C4) healed after stent placement.
*Percentage of limbs that underwent follow-up examination.
Table III. Improvement in swelling after stent placement
Parameter Grade Before stent placement After stent placement
Objective swelling Grade 0 (no swelling) 36 of 297 (12%) 124 of 264 (47%)*
Grades 1 to 3 (swelling; median) 2 (range, 0 to 3) 1 (range, 0 to 3)†
Subjective swelling Grades 0 to 3 n = 62 n = 62
Median 2 (range, 0 to 3) 1 (range, 0 to 3)†
See text for description of grades 1 to 3.
Grade 0: no swelling for both subjective and objective swelling.
*P < .01.
†P < .001.
Table IV. Level of pain before and after stent placement
Pain severity Before stent placement After stent placement
Limbs with no pain 49 of 291 (17%) 185 of 261 (71%)*
Limbs with pain (pain level, 0 to 10; median) 4 (range, 0 to 9) 0 (range, 0 to 9)*
See text for description of pain level.
*P < .001.
The high cost of interventional therapy has to be balanced
against the comparatively low but recurrent and on-going
costs cumulative over the long term of medications, sup-
plies, and healthcare personnel involved in conservative
therapy, including the management of complications and
the staggering indirect costs of work hours lost.10 The
long-term (>10 years) effects of stents in the venous sys-
tem are not known. The follow-up period is short, and
many more years of monitoring are required for the assess-
ment of the efficacy of this therapeutic method in CVI.
The results presented in this study can be considered only
preliminary. However, follow-up periods for cases in the
early part of this series have now extended beyond 3 years
and the clinical benefits appear to have been maintained
without precipitous degradation. Cautious optimism for
this technique therefore appears to be warranted.
Regarding the concern for long-term effects, the experi-
ence with vena cava filters may be relevant. These devices
are not opitimized for laminar flow (unlike the stents),
with most designs presenting a chunk of metal to central
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flow, creating flow turbulence; they have little prospect of
endothelial coverage, and they are often inserted in the
context of ongoing thrombotic event with simultaneous
stoppage of heparin therapy. Yet the patency rate of the fil-
ter insertion site has exceeded 90% up to years.11
Although the technique is minimally invasive, it is not
implied that it is simple. Our technique, as briefly summa-
rized here and described in greater detail elsewhere,2,3 was
empirically derived from an initial experience of 29 limbs2
with more complications and a markedly higher restenosis
rate than in subsequent series. Some of the complications
in the earlier series were undoubtedly related to the learn-
ing curve; substantial technical modifications since have
been made in placement of the stent. Morbidity rates and
technical outcomes have greatly improved since. It is not
known for certain which of these modifications are central
to the improved outcome. The use of ultrasound scan
guidance for femoral vein access has eliminated complica-
tions related to inadvertent arterial puncture. Use of a
large stent (14-mm to 16-mm), extension of the stent into
Table V. Objective swelling and pain severity in limbs with and without ulcer
Before stent placement After stent placement
Objective swelling Pain Objective swelling Pain
Limbs with ulcer (n = 62)
Severity, grade/level (median) 1 (range, 0 to 3) 4 (range, 0 to 9) 0 (range, 0 to 3) 0 (range, 0 to 10)
Limbs with no pain or 14 of 62 (23%)* 13 of 62 (21%) 31 of 53 (58%) 39 of 51 (76%)
objective swelling
Limbs without ulcer (n = 242)
Severity, grade/level (median) 2 (range, 0 to 3) 5 (range, 0 to 9) 1 (range, 0 to 3) 0 (range, 0 to 9)
Limbs with no pain or 24 of 237 (10%)* 39 of 232 (17%) 93 of 211 (44%) 146 of 210 (70%)
objective swelling
See text for description of severity levels.
Limbs without ulcer had significantly higher median grade of swelling and less number of limbs with no swelling (10% versus 23%) before stent placement
than did ulcerated limbs (P < .001), and pain level was same. Both outcome measures improved significantly in both groups after stent placement (P < .001).
*P < .001.
Table VI. Outcome measures when stent placement was performed with or without long saphenous vein ablation
Before stent placement After stent placement
Objective swelling Pain Objective swelling Pain Ulcer
Limbs with ulcer
Stent + LSV (n = 12; 
severity grade/level [median]) 1 (range, 0 to 3) 3 (range, 0 to 8) 0 (range, 0 to 1)* 0 (range, 0 to 0)‡ 6 of 12 (50% healed)
Stent only (n = 37; 
severity grade/level [median]) 1 (range, 0 to 3) 4 (range, 0 to 9) 0 (range, 0 to 3)* 0 (range, 0 to 10)‡ 22 of 37 (59% healed)
Limbs without ulcer
Stent + LSV (n = 49; 
severity grade/level [median]) 1.5 (range, 0 to 3) 5 (range, 0 to 8) 0.5 (range, 0 to 3)† 0 (range, 0 to 8)‡
Stent only (n = 190; 
severity grade/level [median]) 2 (range, 0 to 3) 5 (range, 0 to 9) 1 (range, 0 to 3)‡ 0 (range, 0 to 9) ‡
Addition of long saphenous vein ablation does not appear to influence objective swelling grade or pain level outcome in limbs with or without stasis ulcer.




LSV, Long saphenous vein.
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the vena cava, and use of intraoperative IVUS for the
detection and treatment of all stenotic areas in the iliac
venous segment are believed to be important technical
details in the reduction of the incidence rate of restenosis.
IVUS is invaluable both in diagnosis and as an intraopera-
tive tool in stent placement because contrast venography
even with the transfemoral approach has poor sensitivity in
the assessment of the iliac venous segment.
Thirty-six percent of the limbs in this series had asso-
ciated deep reflux with the obstruction. Relief of obstruc-
tion did not worsen clinically manifested reflux by opening
up the axial channel as has been feared. On the contrary,
healing occurred in the vast majority of cases in this series
with stasis dermatitis or ulceration commonly attributed
to the reflux component. Ninety-one percent of the limbs
with ulcers/dermatitis reported here had associated reflux.
We speculate that the correction of the proximal outflow
obstruction in combined obstruction/reflux allows for the
residual reflux to be more easily tolerated. It remains to be
seen if the initial ulcer healing seen in this series will be
durable over time without the need for additional valve
reconstruction. Our clinical impression is that swelling and
pain of CVI resolve more rapidly and thoroughly than
with valve reconstruction. For the time being, the use of
valve reconstruction procedures in our own practice have
sharply declined since the adoption of stent placement in
eligible limbs when either choice is available.
Surprisingly, nearly half the cases in this series were
classified as nonthrombotic in cause on the basis of intra-
operative IVUS findings. It appears that strictures, webs,
membranes obstructions, and May-Thurner syndrome are
more common causes of venous obstructive symptomatol-
ogy than generally believed. These lesions have been
implicated in the preponderance of the left lower limb in
acute and chronic venous pathology.12-14 Better diagnosis
of these high-grade short length obstructive lesions is
dependent on the use of IVUS because traditional contrast
venography has poor sensitivity in the assessment of the
iliac venous segment for these lesions.4 On the basis of this
preliminary experience, iliac venous stent placement
appears to be a useful method in the management of
patients with CVI.
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Dr Thomas F. O’Donnell, Jr (Boston, Mass). Thank you, Dr
Raju, for e-mailing the various iterations of your manuscript,
which presents the largest experience in the literature on the
treatment of iliac vein occlusive lesions. I think that in this series
you’ve shown that about half were due to standard postthrom-
botic occlusion, the type that we generally treat surgically with a
saphenofemoral or Palma procedure.
The high symptomatic relief of swelling and pain and the
overall low morbidity for stent placement are quite attractive for
this technique. As you emphasized, however, about 14% of your
stent placements required reintervention. By contrast, venous
stenting is a procedure that doesn’t burn any bridges. I have sev-
eral comments and questions.
As you presented, you are appropriately cautious in recom-
mending this form of therapy as the be-all and end-all for iliac
vein lesions. I would echo this caution, but, like you, am intrigued
with your early good results. I have some concerns, however,
about the brevity of the follow-up period, which averaged only 9
months. In addition 13% of the limbs were lost to follow-up,
which is another factor that could bias results. Do you have the
following data not available in the manuscript: (1) the median fol-
low-up time and (2) reasons for the loss of 40 limbs to follow-up
in such a short period of time.
Secondly, for a group that has championed the hemodynamic
evaluation of iliac vein obstruction, and indeed have developed a
specific objective test for it, the “Raju test,” I was really surprised
not to see any mention of preoperative hemodynamic values in this
manuscript. All of us appreciate that patients with leg “pain” are
the most difficult ones to sort out. With a catheter in place in the
iliac vein, did you obtain baseline and post-hyperemic pressures?
Finally, you appear to have mixed apples and oranges in your
manuscript. The iliac vein occlusion patency data were presented
with the iliac stenosis data. Do you have data specifically on the
limbs with postthrombotic occlusion alone? 
DISCUSSION
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I enjoyed your conclusions, with which I agree; the follow-
up is short, and time will tell.
Dr Seshadri Raju. We started performing iliac venous stents 4
years ago. As the initial results were good, the volume has increased
substantially in the last 2 years. This skewed distribution has
resulted in a short median follow-up. Many of the earlier patients
are now beyond 3-year follow-up. It appears that there is no pre-
cipitous degradation of the early good results. We are cautiously
optimistic that the long-term results of the entire series will mirror
the experience in the early subset. The follow-up rate is 87%.
Unfortunately, the percutaneous nature of the procedure in an out-
patient setting has engendered the feeling in some patients that the
procedure was minor. This misconception combined with speedy
resolution of symptoms has resulted in follow-up delinquency.
We have reported on the hemodynamic aspects of the proce-
dure, including intraoperative femoral pressure measurements
and pull through gradients in detail elsewhere. These tests are
positive in only about a third of patients. It appears that this is a
reflection of the poor sensitivity of these pressure-based tests to
identify significant outflow obstruction. Criteria validated in the
arterial system may not apply in the venous circuit. For example,
the contralateral iliac vein flow certainly tends to neutralize or
mask the gradient of iliac vein stenosis. We do not know what a
flow limiting or critical venous stenosis is and if such a concept is
even valid in the venous system.
Seven percent of limbs in this series (17 limbs) had total iliac
occlusions; the rest were stenoses. There were some minor differ-
ences between these two subsets, but overall the clinical results
appear to be substantially similar.
Dr Harry R. Schanzer (New York, NY). The question that I
have has to do with selection. It’s well known, at least from bypass
venous surgery, that in order to have good results you need really
obstructive pattern. I am sure that what you call obstructive/reflux-
ive are patients that have reflux, but they still also have obstruction
in terms of high pressure distally, low pressure proximally, so that
blood flow can go through the stent and not thrombose. Did you
see any difference in results between those obstructive/ refluxive
and the poor obstructive cases?
Second, have you used any ancillary method like AV fistula to
improve patency?
And lastly, are bypasses, like the Palma procedure, out?
Dr Raju. We did not see any difference between pure obstruc-
tion and combined obstruction/reflux limbs.
Palma type of veno-venous bypasses have precipitously
declined in our practice. They are now used only as salvage pro-
cedures when the initial stent procedure had failed. As the
patency rate of iliac venous stent is very high, we have not felt the
need to use adjunctive AV fistula. Among the small number of
stents that have occluded, we have not been able to identify any
specific predictive factors to consider selective use of AV fistula.
Dr Ali F. AbuRahma (Charleston, WVa). We presented our
experience in the Southern Surgical last January and it appears in
the Annals of Surgery just this month. It’s not as large a series as
yours, but our cumulative patency rate of a series of iliac vein PTA
stenting was 69% over 5 years. It’s much longer duration than
yours. But our series was much shorter. We also were somewhat
selective. What I have not seen in your presentation, which you
might have it in your manuscript, have you compared the preop-
erative clinical severity score with the postoperative score? I think
that’s more objective data we could rely on.
Dr Raju. The data presented pertained to severity scores for
specific clinical features such as pain, edema, etc. Overall clinical
severity score and outcome based on reporting standards also sig-
nificantly improved.
Dr Frank T. Padberg, Jr (Newark, NJ). I have two ques-
tions for you. The first has to do with your quality-of-life mea-
sures, of which there are four fairly well validated instruments
available for use: The CIVIQ from Europe; the Aberdeen vari-
cose vein questionnaire; one from this country presented to this
Society 2 years ago by Tony Comerota which had to do with
iliofemoral thrombolysis; and another, specifically dealing with
the ulcer and its effect on quality of life. Were any of these
used? And if so, which?
The second question has to do with ulcer evaluation during
follow-up. While ulcer healing is often a function of attention to
dressings and compliance with local care, the real key is preven-
tion of recurrence! And here, even with a very short follow-up, a
mean of 9 months, you’ve shown us a 64% recurrence rate.
Unfortunately, your slide flashed by so fast I couldn’t see at what
interval of time the ulcer recurrence was noted; however, I would
note that that 60% is similar to the 5-year results reported for
compliant patients with elastic compression stockings. Thus, I
would ask you to compare recurrence of ulcer rather than healing,
since that probably is a more meaningful measurement of suc-
cessful management options.
Dr Raju. We used the CIVIC quality of life questionnaire.
This was among the first such questionnaires to be validated for
use in chronic venous insufficiency and was approved by the
European Consensus Conference headed by Nicolaides. We
started using it routinely 5 years ago before others you referred to
became available.
The cumulative ulcer-free rate—not recurrence—was 64% at
2 years. The stent procedure was not specifically directed toward
the ulcer, but rather the companion symptoms of pain and
swelling. The high ulcer healing rate was therefore quite a sur-
prise and a pleasant byproduct. We have stopped prescribing new
stockings if the patient was not already wearing them, and we
encourage patients to abandon restrictive support use after the
stent procedure if they can tolerate it. The majority are free of
stockings.
